ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ФАРМИНТЕРПРАЙСЕЗ" (RU)
发明人:
Небольсин Владимир Евгеньевич (RU),Константинов Дмитрий Юрьевич (RU),Попова Лариса Леонидовна (RU),Стребкова Елена Алексеевна (RU),Дерябин Петр Григорьевич (RU)
申请号：
RU2012109938/15
公开号：
RU2012109938A
申请日:
2012.03.14
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating viral hepatitis C, comprising administering to the patient an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. The method of claim 1, wherein the viral hepatitis C is acute hepatitis C. 3. The method of claim 1, wherein the viral hepatitis C is chronic hepatitis C. 4. The method of claim 1, wherein the glutaryl histamine is administered as part of the preparation dicarbamine. The method of claim 1, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof is 0.1-10 mg / kg body weight. The method of claim 1, wherein the single dose of glutaryl histamine is 100 mg. The method of claim 1, wherein the duration of glutaryl histamine administration is 3 weeks to 12 months. The method according to claim 1, wherein in the treatment of hepatitis C, the side effects of antiviral therapy are reduced. The method of claim 8, wherein the side effects of antiviral therapy are influenza-like syndrome, arthralgia, myalgia, exacerbation of chronic pancreatitis, depression and / or hair loss. The method of claim 8, wherein the side effects of antiviral therapy are leukopenia or neutropenia. A method of treating viral hepatitis C, comprising administering to the patient an effective amount of pegylated interferon, ribavirin and glutaryl histamine, or a pharmaceutically acceptable salt thereof. The method of claim 11, wherein the viral hepatitis C is acute hepatitis C.13. The method of claim 11, wherein the viral hepatitis C is chronic hepatitis C.14. The method of claim 11, wherein the glutaryl histamine is administered as part of a dicarbamine preparation. The method according to claim 11, where the dose of glutaryl histamine or its pharmaceutically acceptable salt is 0.1-10 mg / kg of weight1. Способ лечения вирусного гепатита С, предусматривающий введение пациенту эффективного количества глутарилгистамина или его фармацевтически приемлемой соли.2. Способ по п.1, где вирусный гепатит С представля
